Pharmacology and pharmacokinetics of rasagiline: A selective, irreversible, second-generation MAO-B inhibitor

Formulary

Volumn 41, Issue SUPPL., 2006, Pages 18-24

  Chen, Jack J ^a,b  

^a LOMA LINDA UNIVERSITY   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMITRIPTYLINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; CARBIDOPA PLUS LEVODOPA; CIMETIDINE; CIPROFLOXACIN; CITALOPRAM; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG METABOLITE; ENTACAPONE; EPHEDRINE; ISOMETHEPTENE; MONOAMINE OXIDASE B INHIBITOR; OMEPRAZOLE; PAROXETINE; PETHIDINE; PHENELZINE; PSEUDOEPHEDRINE; RASAGILINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TYRAMINE;

AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITION; DISEASE COURSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; MENTAL DISEASE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; REVIEW;

EID: 33748501924     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937-1943.
2. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241-248.
3. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561-566.
4. Rascol O, Brooks DJ, Melamed E, et al, for the LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947-954.
5. Hauser RA. Efficacy and safety of rasagiline in the treatment of Parkinson disease. Formulary. 2006;41:31-38.
6. MAO-B inhibitors for the treatment of Parkinson's disease. Mov Disord. 2002;17(suppl 4):S38-S44.
7. Simpson LL. Evidence that deprenyl, a type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine. Biochem Pharmacol. 1978;27:1591-1595.
8. Finberg JP, Youdim MB. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, type A and type B, in the cat. Br J Pharmacol. 1985;85:541-546.
9. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet. 1997;33:91-102.
10. Mahmood I, Marinac JS, Willsie S, Mason WD. Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers. Biopharm Drug Dispos. 1995;16:535-545.
11. Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos. 1997;25:657-662.
12. Cody JT. Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. J Occup Environ Med. 2002;44:435-450.
13. Glezer S, Finberg JP. Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens. Eur J Pharmacol. 2003;472:173-177.
14. Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;63:228-234.
15. Abassi ZA, Binah O, Youdim MB. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol. 2004;143:371-378.
16. Wan FJ, Lin HC, Huang KL, Tseng CJ, Wong CS. Systemic administration of D-amphetamine induces long-lasting oxidative stress in the rat striatum. Life Sci. 2000;66:PL205-PL212.
17. Abu-Raya S, Tabakman R, Blaugrund E, Trembovler V, Lazarovici P. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol. 2002;434:109-116.
18. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol. 1996;40:99-107.
19. Myllyla VV, Sotaniemi KA, Aasly J, et al. An open multicenter study of the efficacy of MDI. 72,974A, a monoamine oxidase type B (MAO-B) inhibitor, in Parkinson's disease. Adv Neurol. 1993;60:676-680.
20. Chen JJ, Shimomura SK. Parkinsonism. In: Herfindal ET, Gourley DR, eds. Textbook of Therapeutics: Drug and Disease Management. 7th ed. Baltimore. Md: Williams & Wilkins; 2000:1139-1155.
21. Riederer P, Youdim MB, Rausch WD, Birkmayer W, Jellinger K, Seemann D. On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm. 1978;43:217-226.
22. Youdim MBH, Finberg JPM. Monoamine oxidase. In: Lajtha A, ed. Handbook of Neurochemistry. Vol 4: Enzymes in the nervous system. 1st ed. New York, NY: Plenum Press; 1983:293-313.
23. Saura Marti J, Kettler R, Da Prada M, Richards JG. Molecular neuroanatomy of MAO-A and MAO-B. J Neural Transm Suppl. 1990;32:49-53.
24. Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine. MPTP, by lira in monoamine oxidase. Biochem Biophys Res Commun. 1984;120:574-578.
25. Heikkila RE, Duvoisin RC, Finberg JP, Youdim MB. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol. 1985;116:313-317.
26. Youdim MB. Platelet monoamine oxidase B: use and misuse. Experientia. 1988;44:137-141.
27. Birkmayer W, Riederer P, Youdim MB, Linauer W. The potentiation of the antiakinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm. 1975;36:303-326.
28. Lamensdorf I, Youdim MB, Finberg JP. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem. 1996;67:1532-1539.
29. Finberg JP, Lamensdorf I, Commissiong JW, Youdim MB. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm. 1996;48(suppl):95- 101.
30. Finberg JP, Wang J, Bankiewicz K, Harvey-White J, Kopin IJ, Goldstein DS. increased striatal dopamine production from L-dopa following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm. 1998;52(suppl):279-285.
31. Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdin MB. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol. 1999;80:495-499.
32. Hubalek F, Binda C, Li M, et al. Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. J Med Chem. 2004;47:1760-1766.
33. Kalir A, Sabbagh A, Youdim MB. Selective acetylenic "suicide" and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol. 1981;73:55-64.
34. Maruyama W, Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech Ageing Dev. 1999;111:189-200.
35. Sterling J, Veinberg A, Lemer D, et al. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl. 1998;52:301-305.
36. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan] , a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132:500-506.
37. Gotz ME, Breithaupt W, Sautter J, et al. Chronic TVP-1012 (rasagiline) dose-activity response of monoamine oxidases A and B in the brain of the common marmoset. J Neural Transm. 1998;52(suppl):271-278.
38. Azilec®t [Prescribing Information]. Kansas City, Mo: Teva Neuroscience: 2006.
39. Rabey JM, Sagi I, Huberman M, et al; Rasagiline Study Group. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000;23:324-330.
40. Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor Pharmacotherapy. 2004;24:1295-1305.
41. Siddiqui MA, Plosker GL. Rasagiline. Drugs Aging. 2005;22:83-91.
42. Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after L-deprenyl (Selegiline) withdrawal. Synapse. 1994;18:86-93.
43. Finberg JPM, Tenne M, Youdim MBH. Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect. In: Youdim MBH, Paykel ES, eds. Monoamine Oxidase Inhibitors: The State of The Art. London, UK: Wiley & Sons; 1981:31-44.
44. Speiser Z, Levy R, Cohen S. Effects of N-propargyl-1-(R)-aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl. 1998;52:287-300.
45. Chen JJ, Berchou RC. Rasagiline, a selective, second-generation, irreversible inhibitor of monoamine oxidase type B, is effective in patients older and younger than 65 years of age with early-to-advanced Parkinson's disease (PD). Pharmacotherapy. 2004;24:1449. Abstract.
46. Goetz CG, Schwid SR, Eberly SW, et al. Safety of rasagiline in elderly Parkinson's disease (PD) patients. Mov Disord. 2005;20(suppl 10):S81. Abstract.
47. Green AR, Mitchell BD, Tordoff AF, Youdim MB. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol. 1977;60:343-349.
48. Fowler JS, Volkow ND, Wang GJ, et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging. 1997;18:431-435.
49. Parkinson Study Group. Rasagiline is effective and well tolerated in the treatment of Parkinson's disease (PD) patients with levodopa-related motor fluctuations receiving other adjunctive therapy. Mov Disord. 2005;20(suppl 10):S138. Abstract.
50. Blindauer K. Tyramine challenge to assess the safety of rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson's disease (the TEMPO study). Neurology. 2001;56(suppl 3):A345. Abstract.
51. de Marcaida JA. Rasagiline does not promote tyramine pressor responses. Mov Disord. 2005;20(suppl 10):S132. Abstract.
52. Jacob JE, Wagner ML, Sage JI. Safety of selegiline with cold medications. Ann Pharmacother. 2003;37:438-441.
53. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003;50:1234-1240.
54. Ondo WG. Rasagiline preclinical studies: implications for neuroprotection. Formulary. 2006;41:25-30.
55. Maruyama W, Akao Y, Youdim MB, Naoi M. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV 1022. J Neural Transm Suppl. 2000;60:171-186.
56. Maruyama W, Takahashi T, Youdim MB, Naoi M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm. 2002;109:467-481.
57. Kupsch A, Sautter J, Gotz ME, et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm. 2001;108:985-1009.
58. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002;326:105-108.
59. Am OB, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett. 2004;355:169-172.
60. Youdim MB, Wadia JS, Tatton WG. Neuroprotective properties of the antiparkinson drug rasagiline and its optical S-isomer. Neurosci Lett. 1999;55:S45.
61. Abu-Raya S, Blaugrund E, Trembovler V, Shilderman-Bloch E, Shohami E, Lazarovici P. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. J Neurosci Res. 1999;58:456-463.
62. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol. 2004;187:455-459.
63. Yogev-Falach M, Amit T, Bar-Am O, Youdim MB. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J. 2003;17:2325-2327.
64. Speiser Z, Katzir O, Rehavi M, Zabarski T, Cohen S. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol Biochem Behav. 1998;60:387-393.
65. Speiser Z, Mayk A, Eliash S, Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm. 1999;106;593-606.
66. Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol. 1999;366:127-135.
67. Eliash S, Speiser Z, Cohen S. Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J Neural Transm. 2001;108:909-923.
68. Eliash S, Shteter N, Eilam R. Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. J Neural Transm. 2005;112:991-1003.